UNSPSC 51332846: Cyamemazine tartrate

This classification denotes a histamine-1 receptor antagonist C19H21N3S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4ZT3BE459, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as cyamemazine tartrate, which bears US NIH Compound Identifier 24892868. European Medicines Agency schedules Cyamemazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01510MIG.

Most nations, for tariff and trade purposes, schedule cyamemazine tartrate under HS 29343090 and SITC 51578. As of Q4 2014, CYAMEMAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)C#N)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51332846 Cyamemazine tartrate is a Commodity code that in practice encompasses broader pharmaceutical procurement by state and local health agencies—specifically naloxone, opioid-reversal agents, generic pharmaceuticals, and over-the-counter health products sourced through competitive bidding and cooperative purchasing frameworks. State and local government buying under this code includes county health departments and state health-and-human-services agencies procuring controlled substances, emergency-response medications, and generic pharmaceutical inventories for public health programs, community health initiatives, and employee benefit plans. Recent solicitations show county governments and state agencies using IFB, RFP, and RFI notice types to establish supply contracts with manufacturers and authorized wholesalers, with requirements for cGMP certification, Drug Supply Chain Security Act compliance, E-Verify verification, and substantial insurance coverage including commercial general liability and professional liability policies.

Recent activity appears concentrated in Florida and Minnesota, with secondary participation from Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually for quarterly delivery to its Community Health Building, with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to work through three authorized wholesalers. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling exploratory procurement likely to advance to formal RFP.